A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.

This study is currently recruiting participants.
Verified October 2013 by C. R. Bard
Information provided by (Responsible Party):
C. R. Bard
ClinicalTrials.gov Identifier:
First received: October 10, 2013
Last updated: NA
Last verified: October 2013
History: No changes posted

The objective of this study is to collect additional data on safety, performance and effectiveness of Phasix™ Mesh in subjects requiring primary ventral, incisional or first-recurrent hernia repair in subjects at high risk for complications. Subjects at high risk are defined as having 1 or more of the following co-morbidity conditions: body mass index (BMI) between 30-40 kg/m2, inclusive, active smokers, chronic obstructive pulmonary disease (COPD), diabetes, immunosuppression, coronary artery disease, chronic corticosteroid use, low pre-operative serum albumin, advanced age, or renal insufficiency.

Condition Intervention
Ventral Hernia
Incisional Hernia
Device: Phasix Mesh

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.

Resource links provided by NLM:

Further study details as provided by C. R. Bard:

Primary Outcome Measures:
  • Hernia Recurrence Rate [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
    Hernia recurrence rates will be assessed by physical examination at each study visit through 24 months. A recurrent hernia will be defined as any hernia identified or confirmed by the investigator, during any study follow-up visit, in approximately the same position as the hernia repaired in the study procedure. Potential hernias identified via incidental magnetic resonance imaging (MRI) or computed tomography (CT) scan will be evaluated by the operating surgeon for clinical significance and confirmation of hernia recurrence.

  • Surgical Site Infections [ Time Frame: 24 Months ] [ Designated as safety issue: Yes ]
    Infections at the surgical site will be assessed by physical examination at each study visit through 24 months. If an infection is suspected, a routine culture, obtained via each site's standard protocol, should be obtained to determine cell count and type (i.e. yeast, gram positive or gram negative bacteria, or other). If genus and species of the culture are identified as part of the routine practice at the site, that information should be recorded. Classification will follow the CDC guidelines for superficial and deep surgical site infections

Secondary Outcome Measures:
  • Pain VAS [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
  • Device related adverse event incidence [ Time Frame: 24 Months ] [ Designated as safety issue: Yes ]
  • Rate of reoperation due to the index hernia repair [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
  • Carolinas Comfort Scale [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
  • SF-12 Questionnaire [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
  • Surgical procedure time as measured from incision to closure [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
  • Length of hospital stay [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: September 2013
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Phasix Mesh Device: Phasix Mesh


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects indicated for primary ventral, incisional or first-recurrent hernia repair with a higher level of risk as defined by the presence of two or more common pre-existing conditions.


Inclusion Criteria:

  1. Subject must be 18 years of age or older
  2. Subject or subject's legally authorized representative must be willing to give written informed consent
  3. Subject must be diagnosed with primary ventral, incisional hernia or first time recurrent ventral or incisional hernia
  4. Subject must have a hernia greater than 10 cm^2 and less than 200 cm^2
  5. Subject must be willing to undergo initial ventral, incisional or first recurrent incisional hernia repair using retro-rectus or onlay placement (using absorbable suture) with or without Component Separation Technique (CST)
  6. Subject is expected to meet the criteria for a Class I wound as defined by the CDC
  7. Subjects must have 1 or more of the following pre-study conditions:

    1. Body Mass Index (BMI) between 30-40 kg/m^2, inclusive
    2. Active smokers (if attempts to quit smoking within two weeks of surgery have failed and the patient is still an active smoker at the time of surgery)
    3. COPD presence on patient self-report
    4. Diabetes mellitus
    5. Immunosuppression
    6. Coronary Artery Disease
    7. Chronic corticosteroid use: greater than 6 months systemic use
    8. Serum albumin less than 3.4 g/dL
    9. Advanced age: 75 years or older
    10. Renal insufficiency, defined as serum creatinine concentration ≥2.5 mg/dL

Exclusion Criteria:

  1. Subject's hernia has recurred more than once
  2. The subject has peritonitis
  3. The subject is on or suspected to be placed on chemotherapy medications during any part of the study
  4. The subject's Body Mass Index (BMI) is greater than 40 kg/m^2
  5. The subject has cirrhosis of the liver and/or ascites
  6. Subject is American Society of Anesthesiology Class 4 or 5
  7. Subject is known to be infected with human immunodeficiency virus (HIV)
  8. Subject has a life expectancy of less than 2 years at the time of enrollment
  9. Subject has any condition that, in the opinion of the Investigator, would preclude the use of the study device, or preclude the subject from completing the follow-up requirements
  10. Subject's hernia repair utilizes intraabdominal mesh placement
  11. Subject has a surgical wound classified as Class II (Clean-Contaminated), Class III (Contaminated) or Class IV (Dirty-Contaminated) as defined by the CDC
  12. Subject has an active or latent systemic infection
  13. Subject requires surgical bridge repair as the sole repair
  14. Subject is pregnant or has plans to become pregnant during the study period or is currently breastfeeding
  15. Subject has enrolled in another clinical study within the last 30 days
  16. Subject is part of the site personnel directly involved with this study
  17. Subject has a known allergy to the test device or component materials
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01961687

Contact: Dawn Heimer 401-825-8681 dawn.heimer@crbard.com

United States, California
University of California, San Diego Not yet recruiting
San Diego, California, United States, 92103
Contact: Sarah Lazar    619-543-2379      
Principal Investigator: Sandler, MD         
United States, Florida
Florida Hospital/Celebration Health Not yet recruiting
Celebration, Florida, United States, 34747
Contact: Kimberly Cartwright    407-303-4235      
Principal Investigator: Parra-Davila, MD         
United States, Indiana
Indiana University Not yet recruiting
Indianapolis, Indiana, United States, 46202
Contact: Jean Lonergan    317-688-3690      
Principal Investigator: Selzer, MD         
United States, Kentucky
University of Kentucky Medical Center Not yet recruiting
Lexington, Kentucky, United States, 40506
Contact: Mandie Zachem    859-323-6346      
Contact: Anna Rockich    859-323-6346      
Principal Investigator: Roth, MD         
United States, Massachusetts
Baystate Medical Center Not yet recruiting
Springfield, Massachusetts, United States, 01199
Contact: Jennifer Germain    413-794-2672      
Contact: Nicole Corriveau    413-794-2672      
Principal Investigator: Earle, MD         
University of Massachusetts Worcester Recruiting
Worcester, Massachusetts, United States, 01655
Contact: Heather Strom    508-856-1729      
Contact: Oksana Babchenko    508-410-3108      
Principal Investigator: Dunn, MD         
United States, Nebraska
Methodist Health System Not yet recruiting
Omaha, Nebraska, United States, 68114
Contact: Lorrie Dohn    402-354-1320      
Contact: Cara Corum    402-354-1320      
Principal Investigator: Anthone, MD         
United States, North Carolina
Southeast Area Health and Education Center Not yet recruiting
Wilmington, North Carolina, United States, 28403
Contact: Chiquta Harris    910-667-9253      
Principal Investigator: Hope, MD         
United States, Oregon
Oregon Health and Science University Not yet recruiting
Portland, Oregon, United States, 97239
Contact: Charlie Borzy    503-494-4949      
Principal Investigator: Martindale, MD         
United States, Tennessee
Univerity of Tennessee Health Science Center Not yet recruiting
Germantown, Tennessee, United States, 38163
Contact: Teresa Riggins    901-866-8530      
Principal Investigator: Voeller, MD         
University of Tennessee Health Sciences Center Not yet recruiting
Knoxville, Tennessee, United States, 37996
Contact: Susan Rawn    865-305-9227      
Principal Investigator: Mancini, MD         
Vanderbilt University Medical Center Not yet recruiting
Nashville, Tennessee, United States, 37232
Contact: Joan Kaiser    615-343-5821      
Principal Investigator: Poulose, MD         
United States, Virginia
Virginia Commonwealth University Not yet recruiting
Richmond, Virginia, United States, 23219
Contact: Donna Neatrour    804-828-0569      
Principal Investigator: Bittner, MD         
United States, Wisconsin
Medical College of Wisconsin Not yet recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Matthew Frelich    414-805-5743      
Principal Investigator: Goldblatt, MD         
Sponsors and Collaborators
C. R. Bard
  More Information

No publications provided

Responsible Party: C. R. Bard
ClinicalTrials.gov Identifier: NCT01961687     History of Changes
Other Study ID Numbers: DVL-HE-011
Study First Received: October 10, 2013
Last Updated: October 10, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hernia, Ventral
Pathological Conditions, Anatomical
Hernia, Abdominal

ClinicalTrials.gov processed this record on April 15, 2014